X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Karuna will obtain exclusive global license to develop, manufacture, and commercialize multiple TRPC4/5 candidates, including lead clinical-stage candidate GFB-887 for the treatment of mood and anxiety disorders.
Lead Product(s): GFB-887
Therapeutic Area: Psychiatry/Psychology Product Name: GFB-887
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Karuna Therapeutics
Deal Size: $535.0 million Upfront Cash: $15.0 million
Deal Type: Licensing Agreement February 02, 2023
Details:
Recent preliminary data from Phase 2 study of GFB-887 in focal segmental glomerular disease (FSGS) further validate feasibility and value of using transplanted human organoids in preclinical PD studies.
Lead Product(s): GFB-887
Therapeutic Area: Nephrology Product Name: GFB-887
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
GFB-024 has the potential to provide disease-modifying effects in the kidney while treating the underlying metabolic dysfunction in obese patients without the CNS side-effects seen by prior small molecule CB1 antagonists.
Lead Product(s): GFB-024
Therapeutic Area: Nephrology Product Name: GFB-024
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
Treatment with GFB-887 led to a statistically significant, clinically meaningful 32% placebo-adjusted mean reduction in urine protein creatine ratio (UPCR), with nine out of ten evaluable patients experiencing a reduction in UPCR.
Lead Product(s): GFB-887
Therapeutic Area: Nephrology Product Name: GFB-887
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2022
Details:
Primary objective of the TRACTION-2 trial is to evaluate the clinical activity of multiple doses of GFB-887 in approximately 78 patients treated for 12 weeks, as measured by percent change from baseline in urine protein to creatine ratio (UPCR) in patients with FSGS.
Lead Product(s): GFB-887
Therapeutic Area: Nephrology Product Name: GFB-887
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2021
Details:
Goldfinch Bio observed that treatment with GFB-024 resulted in inhibition of CB1 receptor signaling, protecting against both podocyte and tubular cell injury, with negligible exposure in the brain and no central nervous system physiological effect.
Lead Product(s): GFB-024
Therapeutic Area: Nephrology Product Name: GFB-024
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2021
Details:
Goldfinch is developing GFB-887, a first-in-class, highly potent and selective inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5), as a precision medicine for patients with kidney diseases characterized by overactivation of the TRPC5-Rac1 pathway.
Lead Product(s): GFB-887
Therapeutic Area: Nephrology Product Name: GFB-887
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
TRACTION-2 is a multicenter, double-blind, randomized, placebo controlled Phase 2 trial evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GFB-887 in approximately 125 patients with FSGS or DN.
Lead Product(s): GFB-887
Therapeutic Area: Nephrology Product Name: GFB-887
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
Proceeds from the Series B financing will enable the advancement of GFB-887 and GFB-024 through three potential clinical proof-of-concept readouts and will also support continued development of the Company’s discovery platform and preclinical pipeline.
Lead Product(s): GFB-887
Therapeutic Area: Nephrology Product Name: GFB-887
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eventide Asset Management
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
